Anavex Life Sciences Corp. (AVXL) financial statements (2020 and earlier)

Company profile

Business Address 51 W 52ND STREET,
NEW YORK, NY 10019-6163
State of Incorp. NV
Fiscal Year End September 30
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27222327915
Cash and cash equivalents27222327915
Receivables43    
Prepaid expense0 1000
Other undisclosed current assets 10000
Total current assets:31252428915
Noncurrent Assets
Property, plant and equipment     0
Deposits noncurrent assets  000 
Total noncurrent assets:  0000
TOTAL ASSETS:31252428915
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:554433
Accounts payable34    
Accrued liabilities22    
Other undisclosed accounts payable and accrued liabilities  4433
Debt     0
Other undisclosed current liabilities    00
Total current liabilities:554433
Noncurrent Liabilities
Long-term debt and lease obligation     0
Long-term debt, excluding current maturities     0
Total noncurrent liabilities:     0
Total liabilities:554433
Stockholders' equity
Stockholders' equity attributable to parent26202024613
Common stock000000
Additional paid in capital1661541291168474
Accumulated deficit(140)(133)(109)(91)(78)(63)
Receivable from officers and directors for issuance of capital stock     2
Total stockholders' equity:26202024613
TOTAL LIABILITIES AND EQUITY:31252428915

Income statement (P&L) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
Operating expenses(29)(29)(19)(16)(16)(7)
Operating loss:(29)(29)(19)(16)(16)(7)
Nonoperating income (expense)43221(5)
Debt instrument, convertible, beneficial conversion feature     7
Interest and debt expense 0(0) 00
Other undisclosed loss from continuing operations before equity method investments, income taxes (0)    
Loss from continuing operations before equity method investments, income taxes:(25)(26)(17)(13)(15)(12)
Other undisclosed income (loss) from continuing operations before income taxes  0 (0)(0)
Loss from continuing operations before income taxes:(25)(26)(17)(13)(15)(12)
Income tax expense(0)(0)(0)(0)(0) 
Net loss available to common stockholders, diluted:(26)(26)(17)(13)(15)(12)

Comprehensive Income ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
Net loss:(26)(26)(17)(13)(15)(12)
Comprehensive loss, net of tax, attributable to parent:(26)(26)(17)(13)(15)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: